“…War€30,000/QALY | [13] | Spain | Apixa vs. Riva €2347/QALY (NHS) Dominant (societal) | €30,000/QALY |
[14] | Spain | Apixa vs. acenocoumarol €13,305/LYG (NHS) €12,765/QALY (NHS) | €30,000/QALY |
[15] | Spain | Apixa vs. Dabi 110 mg €1299/QALY (NHS) Dominant (societal) Apixa vs. Dabi 150 mg €6591/QALY (NHS) €10,676/QALY (societal) | €30,000/QALY |
[16] | UK | Dabi was dominant vs. Riva, Apixa, and War | £25,000/QALY |
[17] | The Netherlands/UK | The Netherlands: Riva: Dominated Apixa: €13,024/QALY Dabi: €14,626/QALY UK: Riva: Dominated Apixa: Dominated Dabi: €11,172/QALY vs. coumarin derivatives | €20,000/QALY and €36,000/QALY |
[18] | Belgium | Apixa vs. aspirin €7334/QALY | €30,000/QALY |
[19] | The Netherlands | Apixa vs. VKAs €10,576/QALY | €20,000/QALY |
[20] | Sweden | Apixa vs. War: SEK 41,453/QALY Aspirin: SEK 41,453/QALY | For War and aspirin, above SEK 35,000 and SEK 45,000 per QALY, respectively |
[21] | France | Aspirin, Dabi, and Riva were dominated by War Apixa vs. War: €12,227/QALY | €30,000/QALY |
[22] | Norway | Sequential Dabi: €15,920/QALY Apixa: €18,955/QALY Riva: €29,990/QALY Dabi 110 mg: €66,121/QALY vs. War | €79,000/QALY (NOK 588,000/QALY) |
[23] | UK | Apixa vs. War: £11,909/QALY Aspirin: £7196/QALY | £20,000/QALY |
[24] | UK | Apixaban vs. Dabi 110: £4497/QALY Dabi 150: £9611/QALY Riva: £5305/QALY | £20,000/QALY |
[25] | |
…”